EAPH (Easton Pharmaceuticals) Cash Flow from Operations: $-0.14 Mil (TTM As of Sep. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EAPH Easton Pharmaceuticals Inc EAPH
12 GF Score
Price $0.00
View Full Analysis

What is Easton Pharmaceuticals Cash Flow from Operations?

Easton Pharmaceuticals EAPH -95.00% 12 Cash Flow from Operations is $-0.14 Mil as of Sep. 2021. GuruFocus rates EAPH with a GF Score™ of 12/100.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2021, Easton Pharmaceuticals's Net Income From Continuing Operations was $-0.08 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.01 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $0.02 Mil. In all, Easton Pharmaceuticals's Cash Flow from Operations for the three months ended in Sep. 2021 was $-0.06 Mil.


Easton Pharmaceuticals  (OTCPK:EAPH) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Easton Pharmaceuticals's net income from continuing operations for the three months ended in Sep. 2021 was $-0.08 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Easton Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Sep. 2021 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Easton Pharmaceuticals's change in working capital for the three months ended in Sep. 2021 was $0.01 Mil. It means Easton Pharmaceuticals's working capital increased by $0.01 Mil from Jun. 2021 to Sep. 2021 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Easton Pharmaceuticals's cash flow from deferred tax for the three months ended in Sep. 2021 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Easton Pharmaceuticals's cash from discontinued operating Activities for the three months ended in Sep. 2021 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Easton Pharmaceuticals's asset impairment charge for the three months ended in Sep. 2021 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Easton Pharmaceuticals's stock based compensation for the three months ended in Sep. 2021 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Easton Pharmaceuticals's cash flow from others for the three months ended in Sep. 2021 was $0.02 Mil.


Easton Pharmaceuticals Cash Flow from Operations Related Terms


Easton Pharmaceuticals Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Easton Pharmaceuticals's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals Cash Flow from Operations Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Cash Flow from Operations
Get a 7-Day Free Trial -0.70 -1.58 -0.01 0.51 -0.19

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.08 -0.00 -0.06
EAPH
12GF Score
Easton Pharmaceuticals Inc EAPH
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easton Pharmaceuticals Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Easton Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Dec. 2020 is calculated as:

Easton Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Sep. 2021 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of $-0.14 Mil mean?
Easton Pharmaceuticals (EAPH) has a Cash Flow from Operations of $-0.14 Mil as of Sep. 2021. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Easton Pharmaceuticals and its competitors.
Is Easton Pharmaceuticals' Cash Flow from Operations too high?
Easton Pharmaceuticals' current Cash Flow from Operations is $-0.14 Mil. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Easton Pharmaceuticals' Cash Flow from Operations compare to FPSUF and GCAN?
Easton Pharmaceuticals' Cash Flow from Operations of $-0.14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Drug Manufacturers company?
A good Cash Flow from Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Easton Pharmaceuticals and its competitors. Easton Pharmaceuticals's current Cash Flow from Operations is $-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easton Pharmaceuticals stock overvalued right now?
Easton Pharmaceuticals (EAPH) has a current Cash Flow from Operations of $-0.14 Mil. The current Cash Flow from Operations is $-0.14 Mil. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current Cash Flow from Operations is $-0.14 Mil as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Easton Pharmaceuticals Business Description

Address 2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
12GF Score

Get the complete analysis for EAPH

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price